

- Brown L, Devesa S. Epidemiologic trends in esophageal and gastric cancer in the United States. *Surg Oncol Clin North Am* 2002;11:235–256.
- Brown LM, Devesa S, Fraumeni JF. Epidemiology of esophageal cancer. In: Posner M, Vokes EE, Weichselbaum RR, eds. *Cancer of the Upper Gastrointestinal Tract*. Hamilton, Ontario: BC Decker; 2002:1.
- Howlander N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute. SEER Web site. [http://seer.cancer.gov/csr/1975\\_2010/](http://seer.cancer.gov/csr/1975_2010/). April 2013.
- Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Schottenfeld D. Epidemiology of cancer of the esophagus. *Semin Oncol* 1984;11:92–100.
- Brown LM, Hoover R, Silverman D, et al. Excess incidence of squamous cell esophageal cancer among US black men: role of social class and other risk factors. *Am J Epidemiol* 2001;153:114–122.
- Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. *Cancer Causes Control* 1993;4:123–132.
- Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst* 1997;89:1277–1284.
- Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. *Gastroenterology* 2012;142:744–753.
- Castellsague X, Munoz N, De Stefani E, et al. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. *Int J Cancer* 1999;82:657–664.
- Castellsague X, Munoz N, De Stefani E, et al. Smoking and drinking cessation and risk of esophageal cancer (Spain). *Cancer Causes Control* 2000;11:813–818.
- Pandeya N, Williams G, Green AC, et al. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. *Gastroenterology* 2009;136:1215–1224.
- Munoz N, Day NE. Esophageal cancer. In: Schottenfeld D, Fraumeni JF, eds. *Cancer Epidemiology and Prevention*. New York: Oxford University Press; 1996:681.
- Qiao Y, Dawsey S, Kamangar F, et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian general population nutrition intervention trial. *J Natl Cancer Inst* 2009;101:507–518.
- Castellsague X, Munoz N, De Stefani E, et al. Influence of mate drinking, hot beverages and diet on esophageal cancer risk in South America. *Int J Cancer* 2000;88:658–664.
- Bravi F, Edefonti V, Randi G, et al. Dietary patterns and the risk of esophageal cancer. *Ann Oncol* 2012;23:765–770.
- Gorey K, Vena JE. Cancer differentials among US blacks and whites: quantitative estimates of socioeconomic-related risks. *J Natl Med Assoc* 1994;86:209–215.
- National Center for Health Statistics. *Health, United States 2000, with Adolescent Health Chartbook*. Hyattsville, MD: NCHS; 2000.
- Vaughan TL, Davis S, Kristal A, et al. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 1995;4:85–92.
- Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the esophagus: role of obesity and diet. *J Natl Cancer Inst* 1995;87:104–109.
- Chow WH, Blot WH, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst* 1998;90:150–155.
- Edelstein ZR, Farrow DC, Bonner MP, et al. Central adiposity and risk of Barrett's esophagus. *Gastroenterology* 2007;133:403–411.
- Ryan AM, Duong M, Healy L, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. *Cancer Epidemiol* 2011;35:309–319.
- Lagergren J. Influence of obesity on the risk of esophageal disorders. *Nat Rev Gastroenterol Hepatol* 2011;8:340–347.
- Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999;340:825–831.
- Chow WH, Finkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. *JAMA* 1995;274:474–477.
- Islami F, Kamangar F. *Helicobacter pylori* and esophageal cancer risk: a meta-analysis. *Cancer Prev Res (Phila)* 2008;1:329–338.
- Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardiac gastric adenocarcinomas associated with *Helicobacter pylori* seropositivity. *J Natl Cancer Inst* 2006;98:1445–1452.
- Ye W, Held M, Lagergren J, et al. *Helicobacter pylori* infection and gastric atrophy: risk of adenocarcinoma and squamous cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. *J Natl Cancer Inst* 2004;96:388–396.
- Cameron AJ. Management of Barrett's esophagus. *Mayo Clin Proc* 1998;73:457–461.
- Spechler SJ. Clinical practice. Barrett's esophagus. *N Engl J Med* 2002;346:836–842.
- Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. *Am J Gastroenterol* 2002;97:1888–1895.
- Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. *JAMA* 2013;310:627–636.
- Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. *Gut* 2012;61:970–976.
- Bhat S, Coleman HC, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. *J Natl Cancer Inst* 2011;103:1049–1057.
- Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med* 2011;365:1375–1383.
- Rudolph RE, Vaughn TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. *Ann Intern Med* 2000;132:612–620.
- Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. *Gastroenterology* 2005;129:1825–1831.
- Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. *Gastroenterology* 2002;122:26–33.
- Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology* 2011;140:1084–1091.
- Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013;108:308–328.
- Evans JA, Early DS, Fukami N, et al. Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. *Gastrointest Endosc* 2012;76:1087–1094.
- Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. *JAMA* 2001;285:2331–2338.
- Chang LC, Oelschlager BK, Quiroga E, et al. Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barrett's esophagus. *Gastrointest Surg* 2006;10:341–346.
- Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. *Gastroenterology* 2002;122:633–640.
- Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. *J Gastrointest Surg* 2002;6:29–35.
- O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. *Am J Gastroenterol* 1999;94:2037–2042.
- van der Burgh A, Dees J, Hop WC, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. *Gut* 1996;39:5–8.
- Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. *BMJ* 2000;321:1252–1255.
- DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. *Ann Surg* 2000;231:303–321.
- Gurski RR, Peters JH, Hagen JA, et al. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. *J Am Coll Surg* 2003;196:706–712.
- Faybush EM, Sampliner RE. Randomized trials in the treatment of Barrett's esophagus. *Dis Esophagus* 2005;18:291–297.
- Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a systematic review and meta-analysis. *Gut* 2013;Nov 12 [Epub ahead of print].
- Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. *Hum Pathol* 1994;25:982–993.
- Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. *Am J Gastroenterol* 2000;95:3383–3387.
- Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. *Hum Pathol* 2001;32:368–378.
- Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. *Gastroenterology* 2002;122:1101–1112.
- Maley C. Multistage carcinogenesis in Barrett's esophagus. *Cancer Lett* 2007;245:22–32.
- Heath E, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. *J Natl Cancer Inst* 2007;99:545–557.
- Ashworth MT, Nash JR, Ellis A, et al. Abnormalities of differentiation and maturation in the oesophageal squamous epithelium of patients with tylosis: morphological features. *Histopathology* 1991;19:303–310.

61. Risk JM, Mills HS, Garde J, et al. The tylosis esophageal cancer (TOC) locus: more than just a familial cancer gene. *Dis Esophagus* 1999;12:173–176.
62. Risk JM, Field EA, Field JK, et al. Tylosis oesophageal cancer mapped. *Nat Genet* 1994;8:319–321.
63. von Brevern M, Hollstein MC, Risk JM, et al. Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q. *Oncogene* 1998;17:2101–2105.
64. Iwaya T, Maesawa C, Ogasawara S, et al. Tylosis esophageal cancer locus on chromosome 17q25.1 is commonly deleted in sporadic human esophageal cancer. *Gastroenterology* 1998;114:1206–1210.
65. Risk JM. Envoplakin, a possible candidate gene for focal NEPPK/esophageal cancer (TOC): the integration of genetic and physical maps of the TOC region on 17q25. *Genomics* 1999;59:234–242.
66. Shamma'A MH, Benedict EB. Esophageal webs; a report of 58 cases & an attempt at classification. *N Engl J Med* 1958;259:378–384.
67. Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, et al. Risk factors for squamous cell carcinoma of the oesophagus. *Br J Surg* 1996;83:1174–1185.
68. Csikos M, Horvath O, Petri A, et al. Late malignant transformation of chronic corrosive oesophageal strictures. *Langenbecks Arch Chir* 1985;365:231–238.
69. Sandler RS, Nyren O, Ekbon A, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. *JAMA* 1995;274:1359–1362.
70. Meijssen MA, Tilanus HW, van Blankenstein M, et al. Achalasia complicated by oesophageal squamous cell carcinoma: a prospective study in 195 patients. *Gut* 1992;33:155–158.
71. Aggestrup S, Holm JC, Sorensen HR. Does achalasia predispose to cancer of the esophagus? *Chest* 1992;102:1013–1016.
72. Loviscek LF, Cenoz MC, Badaloni AE, et al. Early cancer in achalasia. *Dis Esophagus* 1998;11:239–247.
73. Sur M, Cooper K. The role of the human papilloma virus in esophageal cancer. *Pathology* 1998;30:348–354.
74. de Villiers EM, Lavergne D, Chang F, et al. An interlaboratory study to determine the presence of human papillomavirus DNA in esophageal carcinoma from China. *Int J Cancer* 1999;81:225–228.
75. Lavergne D, de Villiers EM. Papillomavirus in esophageal papillomas and carcinomas. *Int J Cancer* 1999;80:681–684.
76. Shibagaki I, Tanaka H, Shimada Y, et al. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. *Clin Cancer Res* 1995;1:769–773.
77. Poljak M, Cerar A, Seme K. Human papillomavirus infection in esophageal carcinomas: a study of 121 lesions using multiple broad-spectrum polymerase chain reactions and literature review. *Hum Pathol* 1998;29:266–271.
78. Rugge M, Bovo D, Busatto G, et al. p53 alterations but no human papillomavirus infection in preinvasive and advanced squamous esophageal cancer in Italy. *Cancer Epidemiol Biomark Prev* 1997;6:171–176.
79. Turner JR, Shen LH, Crum CP, et al. Low prevalence of human papillomavirus infection in esophageal squamous cell carcinomas from North America: analysis by a highly sensitive and specific polymerase chain reaction-based approach. *Hum Pathol* 1997;28:174–178.
80. Lagergren J, Wang Z, Bergstrom R, et al. Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. *J Natl Cancer Inst* 1999;91:156–162.
81. Siewert JR, Feith M, Werner M, et al. Adenocarcinoma of the esophago-gastric junction. Results of surgical therapy based on anatomic-topographic classification in 1,002 consecutive patients. *Ann Surg* 2000;232:353–361.
82. Leon X, Quer M, Diez S, et al. Second neoplasm in patients with head and neck cancer. *Head Neck* 1999;21:204–210.
83. Levi F, Randimbison L, Te VC, et al. Second primary cancers in patients with lung carcinoma. *Cancer* 1999;86:186–190.
84. Narayana A, Vaughan AT, Fisher SG, et al. Second primary tumors in laryngeal cancer: results of long-term follow-up. *Int J Radiat Oncol Biol Phys* 1998;42:557–562.
85. Ribeiro U, Safatle-Ribeiro AV, Posner MC, et al. Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. *Surgery* 1996;120:45–53.
86. Dulak AM, Schumacher SE, van Lieshout J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. *Cancer Res* 2012;72:4383–4393.
87. Dulak AM, Stojanov P, Peng S, et al. Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. *Nat Genet* 2013;5:478–486.
88. Agrawal N, Jiao Y, Bettgowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. *Cancer Discov* 2012;2:899–905.
89. American Joint Commission on Cancer. *AJCC Cancer Staging Manual*. 6th ed. New York: Springer Verlag; 2002.
90. Edge SB, Byrd DR, Compton CC, et al. American Joint Commission on Cancer. *AJCC Cancer Staging Manual*. 7th ed. New York: Springer-Verlag; 2009.
91. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma. Analysis of 100 en bloc esophagectomies. *Ann Surg* 2001;234:520–530.
92. Altorki NK, Girardi L, Skinner DB. En bloc esophagectomy improves survival for stage III esophageal cancer. *J Thorac Cardiovasc Surg* 1997;114:948–955.
93. Akiyama H, Tsurumaru M, Udagawa H, et al. Radical lymph node dissection for cancer of the thoracic esophagus. *Ann Surg* 1994;220:364–372.
94. Altorki N, Kent M, Ferrara C, et al. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. *Ann Surg* 2002;236:177–183.
95. Feith M, Stein JH, Siewert JR. Pattern of lymphatic spread of Barrett's cancer. *World J Surg* 2003;27:1052–1057.
96. Kitagawa Y, Fujii H, Mukai M, et al. Intraoperative lymphatic mapping and sentinel lymph node sampling in esophageal and gastric cancer. *Surg Oncol Clin North Am* 2002;11:293–304.
97. Blot WJ. Epidemiology and genesis of esophageal cancer. In: Roth J, Ruckdeschel JC, Weisenburger TH, eds. *Thoracic Oncology*. Philadelphia PA: WB Saunders; 1995.
98. Medgyesy CD, Wolff RA, Putnam JB Jr, et al. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. *Cancer* 2000;88:262–267.
99. Maier A, Woltsche M, Fell B, et al. Local and systemic treatment in small cell carcinoma of the esophagus. *Oncol Rep* 2000;7:187–192.
100. Kimura H, Konishi K, Maeda K, et al. Highly aggressive behavior and poor prognosis of small-cell carcinoma in the alimentary tract: flow-cytometric analysis and immunohistochemical staining for the p53 protein and proliferating cell nuclear antigen. *Dig Surg* 1999;16:152–157.
101. Ison DH, Minsky BD, Ku CY, et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. *Cancer* 2012;118:2820–2827.
102. Daly JM, Karnell LH, Menck HR. National cancer database report on esophageal carcinoma. *Cancer* 1996;78:1820–1828.
103. Mariette C, Balon JM, Piessen G, et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. *Cancer* 2003;97:1616–1623.
104. Katayama A, Mafune K, Tanaka Y, et al. Autopsy findings in patients after curative esophagectomy for esophageal carcinoma. *J Am Coll Surg* 2003;196:866–873.
105. Kelsen DP, Ginsberg R, Pajak RF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. *N Engl J Med* 1998;339:1979–1984.
106. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. *Lancet* 2002;359:1727–1733.
107. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. *J Clin Oncol* 2001;19:305–313.
108. O'Sullivan G, Sheehan D, Clarke A, et al. Micrometastases in esophagogastriac cancer: high detection rate in resected rib segments. *Gastroenterology* 1999;116:543–548.
109. Bonavina L, Soligo D, Quirici N, et al. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. *Surgery* 2001;129:15–22.
110. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). *Int J Radiat Oncol Biol Phys* 1998;41:579–583.
111. Kleinberg L, Knisely J, Heitmiller R, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys* 2003;56:328–334.
112. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG Trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. *J Clin Oncol* 2007;25:3719–3725.
113. Allum WH, Stenning SP, Bancewicz J, et al. Long term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. *J Clin Oncol* 2009;27:5062–5067.
114. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 1999;281:1623–1627.
115. Denham JW, Steigler A, Kilmurray J, et al. Relapse patterns after chemoradiation for carcinoma of the oesophagus. *Clin Oncol (R Coll Radiol)* 2003;15:98–108.
116. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared to chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 2007;25:1160–1168.
117. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. *J Clin Oncol* 2005;23:2310–2317.
118. Cusio X, Monez-Xiol J, Vilardell F. Endoscopic cytology of cancer of the esophagus and cardia: a long-term evaluation. *Gastrointest Endosc* 1989;35:321–323.
119. Zargar SA, Khuroo MS, Jan GM, et al. Prospective comparison of the value of brushings before and after biopsy in the endoscopic diagnosis of gastroesophageal malignancy. *Acta Cytol* 1991;35:549–552.
120. Jung M, Kiesslich R. Chromoendoscopy and intravital staining techniques. *Baillieres Best Pract Res Clin Gastroenterol* 1999;13:11–19.
121. Acosta MM, Boyce HW Jr. Chromoendoscopy—where is it useful? *J Clin Gastroenterol* 1998;27:13–20.

122. Kara M, Peters FP, Fockens P, et al. Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett's esophagus. *Gastrointest Endosc* 2006;64:176-185.
123. Sharma P, Bansal A, Mathur S, et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. *Gastrointest Endosc* 2006;64:167-175.
124. Ross AS, Noffsinger A, Waxman I. Narrow band imaging directed EMR for Barrett's esophagus with high-grade dysplasia. *Gastrointest Endosc* 2007; 65:166-169.
125. Wolfson HC, Crook JE, Krishna M, et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus. *Gastroenterology* 2008;135:24-31.
126. Gollub MJ, Lefkowitz R, Moskowitz CS, et al. Pelvic CT in patients with esophageal cancer. *AJR Am J Roentgenol* 2005;184:487-490.
127. Lea JW, Prager RL, Bender HW Jr. The questionable role of computed tomography in preoperative staging of esophageal cancer. *Ann Thorac Surg* 1984;38:479-481.
128. Quint LE, Glazer GM, Orringer MB. Esophageal imaging by MR and CT: study of normal anatomy and neoplasms. *Radiology* 1985;156:727-731.
129. Watt I, Stewart I, Anderson D, et al. Laparoscopy, ultrasound and computed tomography in cancer of the oesophagus and gastric cardia: a prospective comparison for detecting intra-abdominal metastases. *Br J Surg* 1989; 76:1036-1039.
130. Becker CD, Barbier P, Porcellini B. CT evaluation of patients undergoing transhiatal esophagectomy for cancer. *J Comput Assist Tomogr* 1986;10: 607-611.
131. Vilgrain V, Mompoin D, Palazzo L, et al. Staging of esophageal carcinoma: comparison of results with endoscopic sonography and CT. *Am J Roentgenol* 1990;155:277-281.
132. Picus D, Balfe D, Koehler RE, et al. Computed tomography in the staging of esophageal carcinoma. *Radiology* 1983;146:433-438.
133. Yoon YC, Lee KS, Shim YM, et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. *Radiology* 2003;227:764-770.
134. Romagnuolo J, Scott J, Hawes RH, et al. Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. *Gastrointest Endosc* 2002;55:648-654.
135. Aibe T, Fuji T, Okita K, et al. A fundamental study of normal layer structure of the gastrointestinal wall visualized by endoscopic ultrasonography. *Scand J Gastroenterol Suppl* 1986;123:6-15.
136. Tio TL, den Hartog Jager FC, Tytgat GN. The role of endoscopic ultrasonography in assessing local resectability of oesophagogastric malignancies. Accuracy, pitfalls, and predictability. *Scand J Gastroenterol Suppl* 1986;123: 78-86.
137. Aibe T, Ito T, Yoshida T, et al. Endoscopic ultrasonography of lymph nodes surrounding the upper GI tract. *Scand J Gastroenterol Suppl* 1986;123:164-169.
138. Catalano MF, Sivak MV Jr, Rice T, et al. Endosonographic features predictive of lymph node metastasis. *Gastrointest Endosc* 1994;40:442-446.
139. Botet JF, Lightdale CJ, Zauber AG, et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. *Radiology* 1991;181:426-432.
140. Tio TL, Cohen P, Coene PP, et al. Endosonography and computed tomography of esophageal carcinoma. Preoperative classification compared to the new (1987) TNM system. *Gastroenterology* 1989;96:1478-1486.
141. Rosch T. Endosonographic staging of esophageal cancer: a review of literature results. *Gastrointest Endosc Clin North Am* 1995;5:537-547.
142. Vazquez-Sequeiros E, Norton ID, Cain JE, et al. Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. *Gastrointest Endosc* 2001;53:751-757.
143. O'Toole D, Palazzo L, Arotcarena R, et al. Assessment of complications of EUS-guided fine-needle aspiration. *Gastrointest Endosc* 2001;53:470-474.
144. Souquet JC, Napoleon B, Pujol B, et al. Endoscopic ultrasonography in the preoperative staging of esophageal cancer. *Endoscopy* 1994;26:764-766.
145. Yoshikane H, Tsukamoto Y, Niwa Y, et al. Superficial esophageal carcinoma: evaluation by endoscopic ultrasonography. *Am J Gastroenterol* 1994;89:702-707.
146. McLoughlin RF, Cooperberg PL, Mathieson JR, et al. High resolution endoluminal ultrasonography in the staging of esophageal carcinoma. *J Ultrasound Med* 1995;14:725-730.
147. Wu LF, Wang BZ, Feng JL, et al. Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. *World J Gastroenterol* 2003;9:219-224.
148. Mallery S, Van Dam J. Increased rate of complete EUS staging of patients with esophageal cancer using the nonoptical, wire-guided echoendoscope. *Gastrointest Endosc* 1999;50:53-57.
149. Willis J, Cooper GS, Isenberg G, et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. *Gastrointest Endosc* 2002;55:655-661.
150. Saltzman JR. Section III: endoscopic and other staging techniques. *Semin Thorac Cardiovasc Surg* 2003;15:180-186.
151. Jost C, Binek J, Schuller JC, et al. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase II study. Swiss Group for Clinical Cancer Research (SAKK 75/02). *Gastrointest Endosc* 2010;7:1114.
152. Flamen P, van Cutsem E, Lerut T, et al. The utility of positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) to predict the pathologic response and survival of esophageal cancer after preoperative chemoradiation therapy (CRT). *Proc Am Soc Clin Oncol* 2001;20:127a.
153. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. *Ann Thorac Surg* 1997;64:765-769.
154. Kole AC, Plukker JT, Nieweg OE, et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. *Br J Cancer* 1998;78:521-527.
155. Plukker JT, van Westreenen JT. Staging in oesophageal cancer. *Best Pract Res Clin Gastroenterol* 2006;20:877-891.
156. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. *J Clin Oncol* 2001;19:3058-3065.
157. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. *J Clin Oncol* 2006;24:4692-4698.
158. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. *Ann Surg* 2001;233:300-309.
159. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. *Lancet Oncol* 2007;8:797-805.
160. zum Büschenfelde CM, Herrmann K, Schuster T, et al. 18F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. *J Nucl Med* 2011;52: 1189-1196.
161. Klaeser B, Nitzsche E, Schuller JC, et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/01). *Onkologie* 2009;32:724-730.
162. Rehlo Aguirre AC, Ramos-Font C, Villegas Portero R, et al. 18F-fluorodeoxyglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature. *Ann Surg* 2009;250:247-254.
163. Kwee R. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with the use of 18F FDG PET: a systematic review. *Radiology* 2010;254:707-717.
164. Dagnini G, Caldironi MW, Marin G, et al. Laparoscopy in abdominal staging of esophageal carcinoma. Report of 369 cases. *Gastrointest Endosc* 1986;32:400-402.
165. Mortensen MB, Scheel-Hincke JD, Madsen MR, et al. Combined endoscopic ultrasonography and laparoscopic ultrasonography in the pretherapeutic assessment of resectability in patients with upper gastrointestinal malignancies. *Scand J Gastroenterol* 1996;31:1115-1119.
166. Luketich JD, Meehan M, Mgyuen NT, et al. Minimally invasive surgical staging for esophageal cancer. *Surg Endosc* 2000;14:700-702.
167. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. *Clin Nucl Med* 2000;25:882-887.
168. Krasna MJ, Jiao X, Mao YS, et al. Thoracoscopy/laparoscopy in the staging of esophageal cancer: Maryland experience. *Surg Laparosc Endosc Percutan Tech* 2002;12:213-218.
169. Wallace MB, Nietert PJ, Earle C, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. *Ann Thorac Surg* 2002;74:1026-1032.
170. Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. *J Thorac Cardiovasc Surg* 2005;132:1374-1381.
171. Lagarde SM, Ten Kate FJ, Reitsma JB, et al. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. *J Clin Oncol* 2006;24:4347-4355.
172. Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Worldwide Esophageal Cancer Collaboration. *Cancer* 2010;116:3763-3773.
173. Merkow RP, Bilimoria KY, McCarter MD. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. *Ann Surg Oncol*. 2012;19:357-364.
174. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. *J Thorac Cardiovasc Surg* 1994;108:813-821.
175. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. *Ann Surg* 1996;224:66-71.
176. Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. *Gastrointest Endosc* 1999;49:170-176.
177. Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. *Ann Surg* 1999;230:433-438.



178. Stein HJ, Feiht M, Brucher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. *Ann Surg* 2005;242:566–573.
179. Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. *Am J Gastroenterol* 2012;107:850–862.
180. Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. *Gastrointest Endosc* 2008;67:394–398.
181. Pacifico RJ, Want KK. Nonsurgical management of Barrett's esophagus with high-grade dysplasia. *Surg Oncol Clin North Am* 2002;11:321–336.
182. Konda VJ, Ross AS, Ferguson MK. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? *Clin Gastroenterol Hepatol* 2008;6:159–164.
183. Romagnoli R, Collard JM, Gutschow C, et al. Outcomes of dysplasia arising in Barrett's esophagus: a dynamic view. *J Am Coll Surg* 2003;197:365–371.
184. Levine DS, Haggitt RC, Blout PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. *Gastroenterology* 1993;105:40–50.
185. Cameron AJ. Barrett's esophagus: does the incidence of adenocarcinoma matter? *Am J Gastroenterol* 1997;92:193–194.
186. Dar MS, Goldblum JR, Rice TW, et al. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? *Gut* 2003;52:486–489.
187. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. *Gastrointest Endosc* 2005;62:488–498.
188. Gossner L, May A, Stolte M, et al. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. *Gastrointest Endosc* 1999;49:8–12.
189. Sharma P, Jaffe PE, Bhattacharyya A, et al. Laser and multipolar electrocoagulation ablation of early Barrett's adenocarcinoma: long-term follow-up. *Gastrointest Endosc* 1999;49:442–446.
190. Morris CD, Byrne JP, Armstrong GR, et al. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. *Br J Surg* 2001;88:1357–1362.
191. Van Laethem JL, Jagodzinski R, Peny MO, et al. Argon plasma coagulation in the treatment of Barrett's high-grade dysplasia and in situ adenocarcinoma. *Endoscopy* 2001;33:257–261.
192. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus and dysplasia. *N Engl J Med* 2009;360:2277–2288.
193. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). *Gastrointest Endosc* 2007;65:3–10.
194. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. *Gastroenterology* 2000;118:670–677.
195. Shami VM, Villaverde A, Stearns L, et al. Clinical impact of conventional endosonography and endoscopic ultrasound-guided fine-needle aspiration in the assessment of patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma who have been referred for endoscopic ablation therapy. *Endoscopy* 2006;38:157–161.
196. Nijhawan K, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. *Gastrointest Endosc* 2000;52:328–332.
197. Yoshida M, Hanashi T, Momma K, et al. Endoscopic mucosal resection for radical treatment of esophageal cancer. *Gan To Kagaku Ryoho* 1995;22:847–854.
198. Chennat J, Konda V, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma—an American single-center experience. *Am J Gastroenterol* 2009;104:2684–2692.
199. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. *Gastroenterology* 2012;143:336–346.
200. Swanstrom LL, Hansen P. Laparoscopic total esophagectomy. *Arch Surg* 1997;132:943–947.
201. Luketich JD, Schauer PR, Christie NA, et al. Minimally invasive esophagectomy. *Ann Thorac Surg* 2000;70:906–911.
202. Posner MC, Alverdy J. Hand-assisted laparoscopic surgery for cancer. *Cancer J* 2002;8:144–153.
203. Osugi H, Takemura M, Higashino M, et al. Video-assisted thoracoscopic esophagectomy and radical lymph node dissection for esophageal cancer. A series of 75 cases. *Surg Endosc* 2002;16:1588–1593.
204. Dunn DH, Johnson EM, Morpew JA, et al. Robot-assisted transhiatal esophagectomy: a 3-year single-center experience. *Dis Esophagus* 2013;26:159–166.
205. Luketich JD, Pennathur A, Awais O. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. *Ann Surg* 2012;256:95–103.
206. Pennathur A, Farkas A, Krasinskas AM, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. *Ann Thorac Surg* 2009;87:1048–1054.
207. Law S, Wong J. Use of minimally invasive esophagectomy for cancer of the oesophagus. *Lancet Oncol* 2002;3:215–222.
208. Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. *Lancet Oncol* 2003;4:481–488.
209. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. *Lancet* 2012; 379:1887–1892.
210. Sai H, Mitsumori M, Arai K, et al. Long-term results of definitive radiotherapy for stage I esophageal cancer. *Int J Radiat Oncol Biol Phys* 2005;62:1339–1344.
211. Yamada K, Murakami M, Okamoto Y, et al. Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2006;64:1106–1111.
212. Matori M, Yanon M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1b-N0M0 esophageal cancer. *Ann Surg Oncol* 2012;19:2135–2141.
213. Swisher SG, Deford L, Merriman KW, et al. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. *J Thorac Cardiovasc Surg* 2000;119:1126–1132.
214. Begg CB, Cramer LD, Hoskins WJ, et al. Impact of hospital volume on operative mortality for major cancer surgery. *JAMA* 1998;280:1747–1751.
215. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med* 2002;346:1128–1137.
216. Verhoef C, van de Weyer R, Schaapveld M, et al. Better survival in patients with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologists. *Ann Surg Oncol* 2007;14:1678–1687.
217. Halm EA, Lee C, Chassini MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. *Ann Intern Med* 2002;137:511–520.
218. Wouters MW, Karin-Kos H, le Cessie S, et al. Centralization of esophageal cancer surgery: does it improve clinical outcomes? *Ann Surg Oncol* 2009;16:1789–1798.
219. Reames BN, Ghaferi AA, Birkmeyer JD, et al. Hospital Volume and Operative Mortality in the Modern Era. *Ann Surg* 2013 Dec 23 [Epub Ahead of Print].
220. Posner MC. Techniques of esophageal resection. In: Posner MC, Vokes EE, Weichselbaum RR, eds. *Cancer of the Upper Gastrointestinal Tract*. Hamilton, Ontario: BC Decker; 2002:1.
221. Park JO, Posner MC. Standard surgical approaches in the management of esophageal cancer. *Surg Oncol Clin North Am* 2002;11:351–363.
222. Fok M, Cheng SW, Wong J. Pyloroplasty versus no drainage in gastric replacement of the esophagus. *Am J Surg* 1991;162:447–452.
223. Urschel JD, Blewett CJ, Young JE, et al. Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials. *Dig Surg* 2002;19:160–164.
224. Bumm R, Feussner H, Bartels H, et al. Radical transhiatal esophagectomy with two-field lymphadenectomy and endodissection for distal esophageal adenocarcinoma. *World J Surg* 1997;21:822–831.
225. Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. *Ann Surg* 2007;246:363–372.
226. Orringer MB, Marshall B, Jannetoni MD. Transhiatal esophagectomy: clinical experience and refinements. *Ann Surg* 1999;230:392–400.
227. Gelfand GA, Finley RJ, Nelems B, et al. Transhiatal esophagectomy for carcinoma of the esophagus and cardia. Experience with 160 cases. *Arch Surg* 1992;127:1164–1167.
228. Vigneswaran WT, Visset J, Paineau J, et al. Transhiatal esophagectomy for carcinoma of the esophagus. *Ann Thorac Surg* 1993;56:838–844.
229. Gertsch P, Vauthey JN, Lustenberger AA, et al. Long-term results of transhiatal esophagectomy for esophageal carcinoma. A multivariate analysis of prognostic factors. *Cancer* 1993;72:2312–2319.
230. Bolton JS, Teng S. Transthoracic or transhiatal esophagectomy for cancer of the esophagus—does it matter? *Surg Oncol Clin North Am* 2002;11:365–375.
231. Dudhat SB, Shinde SR. Transhiatal esophagectomy for squamous cell carcinoma of the esophagus. *Dis Esophagus* 1998;11:226–230.
232. McKeown KC. Total three-stage oesophagectomy for cancer of the oesophagus. *Br J Surg* 1976;63:259–262.
233. Linden A, Sugarbaker DJ. Section V: techniques of esophageal resection. *Semin Thorac Cardiovasc Surg* 2003;15:197–209.
234. Bizekis C, Kent MS, Luketich JD, et al. Initial experience with minimally invasive Ivor Lewis esophagectomy. *Ann Thorac Surg* 2006;82:402–406.
235. Sharpe DA, Moghissi K. Resectional surgery in carcinoma of the esophagus and cardia: what influences long-term survival? *Eur J Cardiothorac Surg* 1996;10:359–363.
236. Ellis FH Jr. Standard resection for cancer of the esophagus and cardia. *Surg Oncol Clin North Am* 1999;8:279–294.
237. Adam DJ, Craig SR, Sang CT, et al. Oesophagogastronomy for carcinoma in patients under 50 years of age. *J R Coll Surg Edinb* 1996;41:371–373.
238. Wang LS, Huang MH, Huang BS, et al. Gastric substitution for resectable carcinoma of the esophagus: an analysis of 368 cases. *Ann Thorac Surg* 1992;53:289–294.
239. Lieberman MD, Shriver CD, Bleckner S, et al. Carcinoma of the esophagus. Prognostic significance of histologic type. *J Thorac Cardiovasc Surg* 1995;109:130–138.
240. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. *N Engl J Med* 1997;337:161–167.

241. Rindani R, Martin CJ, Cox MR. Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference? *Aust N Z J Surg* 1999;69:187-194.
242. Hulscher JB, Tjissen JG, Obertop H, et al. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. *Ann Thorac Surg* 2001;72:306-313.
243. Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. *Ann Surg* 2011;254:894-906.
244. Rentz J, Bull D, Harpole D, et al. Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients. *J Thorac Cardiovasc Surg* 2003;125:1114-1120.
245. Chang AC, Ji J, Birkmeyer NJ, et al. Outcomes after transhiatal and transthoracic esophagectomy for cancer. *Ann Thorac Surg* 2008;85:424-429.
246. Goldminc M, Maddern G, LePrise E, et al. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. *Br J Surg* 1993;80:367-370.
247. Jacobi CA, Zieren HU, Muller JM, et al. Surgical therapy of esophageal carcinoma: the influence of surgical approach and esophageal resection on cardiopulmonary function. *Eur J Cardiothorac Surg* 1997;11:32-37.
248. Chu KM, Law SY, Fok M, et al. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. *Am J Surg* 1997;174:320-324.
249. Hulscher JB, van Sandick JW, deBoer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. *N Engl J Med* 2002;347:1662-1669.
250. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of randomized clinical trial. *Ann Surg* 2007;246:992-1000.
251. Skinner DB. En bloc resection for neoplasms of the esophagus and cardia. *J Thorac Cardiovasc Surg* 1983;85:59-71.
252. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. *Ann Surg* 2004;240:962-972.
253. Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. *Am J Surg* 1998;175:47-51.
254. Coonley CJ, Bains M, Hilaris B, et al. Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final report. *Cancer* 1984;54:2351-2355.
255. Kelsen D, Hilaris B, Coonley C, et al. Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma. *Am J Med* 1983;75:645-652.
256. Schlag P, Hermann R, Raeth V, et al. Preoperative chemotherapy in esophageal cancer. A phase II study. *Acta Oncol* 1988;27:811-814.
257. Forastiere AA, Gennis M, Orringer MB, et al. Cisplatin, vinblastine, and mitoguanzone chemotherapy for epidermoid and adenocarcinoma of the esophagus. *J Clin Oncol* 1987;5:1143-1149.
258. Carey RW, Hilgenberg AD, Wilkins EW, et al. Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. *Cancer Invest* 1993;11:99-105.
259. Kies MS, Rosen ST, Tsang TK, et al. Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. *Cancer* 1987;60:2156-2160.
260. Ajani JA, Ryan B, Rich TA, et al. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. *Eur J Cancer* 1992;28A:880-884.
261. Vignoud J, Visset J, Paineau J, et al. Preoperative chemotherapy in squamous cell carcinoma of the esophagus: clinical and pathological analysis, 48 cases. *Ann Oncol* 1990;1:45.
262. Wright CD, Mathiesen DJ, Wain JC, et al. Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction. *Ann Thorac Surg* 1994;58:1574-1578.
263. Nygaard K, Hagen S, Hansen JS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. *World J Surg* 1992;16:1104-1110.
264. Roth JA, Pass HI, Flanagan MM, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. *J Thorac Cardiovasc Surg* 1988;96:242-248.
265. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. *Arch Surg* 1992;127:1446-1450.
266. Cunningham D, Allum W, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20.
267. Yehou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNLC and FFCF multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721.
268. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organization for Research and Treatment of Cancer randomized Trial 40954. *J Clin Oncol* 2010;28:5210-5218.
269. Boonstra JJ, Kok TC, Wijnhoven BPL, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized trial. *BMC Cancer* 2011;11:181.
270. Thirion PG, Michiels S, LeMaitre A, et al. Individual patient data based meta analysis assessing preoperative chemotherapy in resectable oesophageal cancer. *J Clin Oncol* 2007;25:4512.
271. Mei W, Xian-Zhi G, Weibo Y, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. *Int J Radiat Oncol Biol Phys* 1989;16:325-327.
272. Gignoux M, Roussel A, Paillot B, et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the EORTC. *World J Surg* 1987;11:426-432.
273. Teniere P, Hay JM, Fingerhut A, et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. *Surg Gynecol Obstet* 1991;173:123.
274. Launois B, Delaru D, Campion JP, et al. Preoperative radiotherapy for carcinoma of the esophagus. *Surg Gynecol Obstet* 1981;153:690-692.
275. Arnott SJ, Duncan W, Kerr GR, et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. *Radiation Oncol* 1993;24:108-113.
276. Huang GJ, Gu XZ, Wang LJ, et al. Combined preoperative irradiation and surgery for esophageal carcinoma. In: Delalrue NC, ed. *International Trends in General Thoracic Surgery*. St. Louis: Mosby; 1988:315.
277. Jacob JH, Seitz JF, Langlois C, et al. Definitive concurrent chemoradiation therapy (CRT) in squamous cell carcinoma of the esophagus (SCCE): preliminary results of a French randomized trial comparing standard vs. split course irradiation (FNLC-FFCD 9305). *Proc Am Soc Clin Oncol* 1999;18: (abst 270a).
278. Yadava OP, Hodge AJ, Matz LR, et al. Esophageal malignancies: is preoperative radiotherapy the way to go? *Ann Thorac Surg* 1991;51:189-193.
279. Sugimachi K, Matsufuji H, Kai H, et al. Preoperative irradiation for carcinoma of the esophagus. *Surg Gynecol Obstet* 1986;162:174-176.
280. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* 1992;326:1593-1598.
281. Minsky B, Pajak T, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20:1167-1174.
282. Poplin E, Fleming T, Leichman L, et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). *J Clin Oncol* 1987;5:622-628.
283. Naunheim KS, Petruska P, Roy TS, et al. Preoperative chemotherapy and radiotherapy for esophageal carcinoma. *J Thorac Cardiovasc Surg* 1992;103:887-893.
284. Forastiere A, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. *J Clin Oncol* 1993;11:1118-1123.
285. Forastiere A, Orringer MB, Perez-Tamayo C, et al. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. *J Clin Oncol* 1990;8:119-127.
286. Hoff SJ, Stewart JL, Murray MK, et al. Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. *Ann Thorac Surg* 1993;56:282-286.
287. Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. *J Clin Oncol* 1996;14:156-163.
288. Malhaire JP, Labat JP, Lozach P, et al. Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. *Int J Radiat Oncol Biol Phys* 1996;34:429-437.
289. Stahl M, Wilke H, Fink U, et al. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: interim analysis of a phase II trial. *J Clin Oncol* 1996;14:829-837.
290. Forastiere AA, Heitmler RF, Lee DJ, et al. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. *Cancer J Sci Am* 1997;3:144-152.
291. Jones DR, Detterbeck FC, Egan TM, et al. Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. *Ann Thorac Surg* 1997;64:185-191.
292. Adelstein DJ, Rice TW, Rybicki LA, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal cancer. *Cancer* 1997;80:1011-1020.
293. Posner MC, Gooding WE, Landreneau RJ, et al. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. *Cancer J Sci Am* 1998;4:237-246.
294. Posner MC, Gooding WE, Lew JL, et al. Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal cancer. *Surgery* 2001;130:620-626.
295. Raoul JL, LePrise E, Meunier B, et al. Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 1998;42:29-34.

296. Keller SM, Ryan L, Coia LR, et al. High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction. Results of a phase II study of the Eastern Cooperative Oncology Group. *Cancer* 1998;83:1908–1916.
297. Bedenne L, Seitz JF, Milan C, et al. Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study. *Gastroenterol Clin Biol* 1998;22:273–281.
298. Laterza E, deManzoni G, Tedesco P, et al. Induction chemo-radiotherapy for squamous cell carcinoma of the thoracic esophagus: long-term results of a phase II study. *Ann Surg Oncol* 1999;6:777–784.
299. Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. *J Clin Oncol* 2000;18:868–876.
300. Roof KS, Coen J, Lynch TJ, et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 2006;65:1120–1128.
301. Meredith K, Weber J, Turaga K, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. *Ann Surg Oncol* 2010;17:1159–1167.
302. Leichman LP, Goldman BH, Bohanes PO, et al. S0356: A phase II clinical and a prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. *J Clin Oncol* 2011;29:4555–4560.
303. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. *Cancer Invest* 2001;19:1–7.
304. Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A non-randomized comparison with fluorouracil-based therapy. *J Clin Oncol* 2000;18:2032–2039.
305. Wright CD, Wain JC, Lynch TJ, et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. *J Thorac Cardiovasc Surg* 1997;114:811–815.
306. Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. *Cancer J* 2003;9:251–260.
307. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. *J Thorac Cardiovasc Surg* 2002;124:270–277.
308. Swisher SG, Ajani JA, Komaki R, et al. Long term outcome of a phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 2003;57:120–127.
309. Ajani JA, Corea A, Walsh G, et al. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. *Cancer* 2010;116:1656–1663.
310. van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. *Br J Cancer* 2006;94:1389–1394.
311. Spigel DR, Greco A, Meluch AA, et al. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. *J Clin Oncol* 2010;28:2213–2219.
312. Ajani JA, Winter KA, Komaki R, et al. Phase II randomized trial of two non-operative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. *J Clin Oncol* 2008;26:4551–4556.
313. Ison D, Goodman KA, Janjigian YY, et al. Phase II trial of bevacizumab, irinotecan, cisplatin and radiation as preoperative therapy in esophageal adenocarcinoma. *J Clin Oncol* 2012;30:4061.
314. Rivera F, Galan M, Taberero J, et al. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. *Int J Rad Oncol Biol Phys* 2009;75:1430.
315. Leichman L, Steiger Z, Seydel HG, et al. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. *J Clin Oncol* 1984;2:75–79.
316. Geh JI, Bond SJ, Bentzen SM, et al. Systematic overview of preoperative (neoadjuvant) hemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. *Radiother Oncol* 2006;78:236–244.
317. Van Hagen P, Hulshof MC, van Lanschoot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012;366:2074–2084.
318. Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. *Ann Surg* 2009;249:764–767.
319. Chedella NKS, Suzuki A, Xiao L, et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. *Ann Oncol* 2013;24:1262.
320. Yang Q, Cleary KR, Yao JC, et al. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. *Dis Esophagus* 2004;14:38–43.
321. Jones DR, Parker LA, Detterbeck FC, et al. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. *Cancer* 1999;85:1026–1032.
322. Zuccaro G Jr, Rice TW, Goldblum J, et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. *Am J Gastroenterol* 1999;94:906–912.
323. Laterza E, deManzoni G, Guglielmi A, et al. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. *Ann Thorac Surg* 1999;67:1466–1469.
324. Beseth BD, Bedford R, Isacoff WH, et al. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. *Am Surg* 2000;66:827–831.
325. Gaca JC, Petersen RP, Peterson BL, et al. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. *Ann Surg Oncol* 2006;13:340–346.
326. Fields RC, Strong VE, Gonen M, et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastroesophageal adenocarcinoma. *Br J Cancer* 2011;104:1840–1847.
327. Downey RJ, Akhurst T, Ison D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. *J Clin Oncol* 2003;21:428–432.
328. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. *Ann Oncol* 2002;13:361–368.
329. Vallbohmer D, Holscher AH, Dietlein M, et al. [18F] fluorodeoxyglucose-positron emission tomography for the assessment of histologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. *Ann Surg* 2009;250:888–894.
330. Klayton T, Li T, Yu JQ, et al. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. *J Gastrointest Surg* 2012;43:612–618.
331. Suzuki A, Xiao L, Taketa T, et al. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. *Ann Oncol* 2013;24:2854–2859.
332. Monjazeb AM, Riedlinger C, Akilu M, et al. Outcomes of patients with esophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can post-radiochemotherapy FDG-PET predict the utility of resection? *J Clin Oncol* 2010;28:4714–4721.
333. Brenner B, Ison D, Minsky B, et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. *J Clin Oncol* 2004;22:45–52.
334. McCurdy M, McAleer MF, Wei W, et al. Induction and concurrent taxanes enhance both the pulmonary metabolic response and the radiation pneumonitis response in patients with esophagus cancer. *Int J Radiat Oncol Biol Phys* 2010;76:816–823.
335. Urba SG, Orringer MB, Iannettoni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. *Cancer* 2003;98:2177–2183.
336. Urba S, Hayman M, Iannettoni M, et al. Preoperative chemoradiation with cisplatin, 5-FU, and paclitaxel followed by surgery and adjuvant chemotherapy for locoregional esophageal cancer. *J Clin Oncol* 2004;22:4029.
337. Kleinberg L, Powell ME, Forastiere AA, et al. Survival outcome of E1201: an Eastern Cooperative Oncology Group randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy or irinotecan/cisplatin/radiotherapy in endoscopy with ultrasound stage esophageal adenocarcinoma. *J Clin Oncol* 2008;26:4532.
338. Kleinberg LR, Eapen S, Hamilton S, et al. E1201: an Eastern Cooperative Oncology Group (ECOG) randomized phase II trial to measure response rate and toxicity of preoperative combined modality paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in adenocarcinoma of the esophagus. *Int J Rad Oncol Biol Phys* 2006;66:s173.
339. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. *N Engl J Med* 1996;335:462–467.
340. Walsh TN, Grennell M, Mansoor S, et al. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. *Dis Esophagus* 2002;15:121–124.
341. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. *Lancet Oncol* 2005;6:659–668.
342. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086–1092.
343. Lee J, Kim S, Jung H, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. *Ann Oncol* 2004;15:947–954.
344. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. *J Clin Oncol* 2009;27:851–856.
345. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. *Cancer* 1994;73:1779–1784.



346. Kaklamano IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for resectable cancer of the esophagus and gastroesophageal junction: a meta-analysis of randomized clinical trials. *Ann Surg Oncol* 2003;10:754-761.
347. Sjoquist KM, Burnmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. *Lancet Oncol* 2011;12:681-692.
348. Bendell JC, Meluch A, Peyton J, et al. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. *Clin Adv Hematol Oncol* 2012;10:430-437.
349. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with esophageal cancer (SCOPE-1): a multicenter, phase 2/3 randomized trial. *Lancet Oncol* 2013;14:627-637.
350. Suntharalingam M, Winter KW, Ilson D, et al. The initial Report of RTOG 0436: A Phase III Trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. 2014 LBA GI Symposium 2014.
351. Safran H, Diprettilo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin, and radiation for locally advanced, HER2-over expressing esophageal adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2007;67:405-409.
352. A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Japanese Esophageal Oncology Group. *Chest* 1993;104:203-207.
353. Iizuka AT, Isono KK, Watanabe H, et al. A randomized trial comparing surgery to surgery plus postoperative chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Study Group (JCOG) study. *Proc Am Soc Clin Oncol* 1998;17:282a.
354. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. *J Thorac Cardiovasc Surg* 1997;114:205-209.
355. Iizuka T. Surgical adjuvant treatment of esophageal carcinoma: a Japanese Esophageal Oncology Group Experience. *Semin Oncol* 1994;21:462-466.
356. Armanios MY, Xu R, Forastiere A, et al. Phase II adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal (GE) junction and cardia (8296): A trial of the Eastern Cooperative Oncology Group. *Proc Am Soc Clin Oncol* 2003;22:4495-4499.
357. Yamamoto M, Yamashita T, Matsubara T, et al. Reevaluation of postoperative radiotherapy for thoracic esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 1997;37:75-78.
358. Hosokawa M, Shirato H, Ohara K, et al. Intraoperative radiation therapy to the upper mediastinum and nerve-sparing three-field lymphadenectomy followed by external beam radiotherapy for patients with thoracic esophageal carcinoma. *Cancer* 1999;86:6-13.
359. Fok M, Sham JS, Choi D, et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. *Surgery* 1993;113:138-147.
360. MacDonald J, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT 0116 (SWOG 9008). *Proc Am Soc Clin Oncol* 2009;27:205s.
361. Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. *Ann Oncol* 2013;24:1754-1761.
362. Okawa T, Kita M, Tanaka M, et al. Results of radiotherapy for inoperable locally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 1989;17:49-54.
363. al-Sarraf M, Martz K, Herskovic A, et al. Superiority of chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients with esophageal cancer. Final report of an Intergroup randomized and confirmed study. *Proc Am Soc Clin Oncol* 1996;15:abst 206.
364. Suntharalingam M, Moughhan J, Cola LR, et al. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. *J Clin Oncol* 2005;23:2325-2331.
365. Gomi K, Oguchi M, Hirokawa Y, et al. Process and preliminary outcome of a patterns of care study of esophageal cancer in Japan: patients treated with surgery and radiotherapy. *Int J Radiat Oncol Biol Phys* 2003;56:813-822.
366. De-Ren S. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. *Int J Radiat Oncol Biol Phys* 1989;16:329-334.
367. Newashy GA, Read GA, Duncan W, et al. Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. *Clin Radiol* 1982;33:347-352.
368. Shi X, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. *Radiother Oncol* 1999;51:21-26.
369. Coia LR, Engstrom PF, Paul AR, et al. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 1991;20:29-36.
370. Nemoto K, Yamada S, Hareyama M, et al. Radiation therapy for superficial esophageal cancer: a comparison of radiotherapy methods. *Int J Radiat Oncol Biol Phys* 2001;50:639-644.
371. Roussel A, Jacob JH, Jung GM, et al. Controlled clinical trial for the treatment of patients with inoperable esophageal carcinoma: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. In: Schlag P, Hohenberger P, Metzger U, eds. *Recent Results in Cancer Research*. Berlin: Springer-Verlag; 1988: 21.
372. al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an Intergroup study. *J Clin Oncol* 1997;15:277-284.
373. Slabber CF, Nel JS, Schoeman L, et al. A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus. *Am J Clin Oncol* 1998;21:462-465.
374. Smith TJ, Ryan LM, Douglass HO, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. *Int J Radiat Oncol Biol Phys* 1998;42:269-276.
375. Araujo C, Souhami L, Gil R, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. *Cancer* 1991;67:2258-2261.
376. Wong RK, Malthaner RA, Zuraw L, et al. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. *Int J Radiat Oncol Biol Phys* 2003;55:910-942.
377. Streeter OE Jr, Martz KL, Caspar LE, et al. Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01? *Int J Radiat Oncol Biol Phys* 1999;44:1047-1052.
378. Yu J, Ren R, Sun X, et al. A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer. *Proc Am Soc Clin Oncol* 2006;24:181s.
379. Chiu PWY, Chan ACW, Leung SF, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). *J Gastrointest Surg* 2005;9:794.
380. Minsky BD, Neuberger D, Kelsen DP, et al. Final report of Intergroup trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. *Int J Radiat Oncol Biol Phys* 1999;43:517-523.
381. Bonnetain F, Bedenne L, Michel P, et al. Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs. radiochemotherapy in patients with locally advanced esophageal cancer). *Proc Am Soc Clin Oncol* 2003;22:250.
382. Crehange G, Maingon P, Peignaux K, et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal cancer: Federation Francophone de Cancerologie Digestive 9102. *J Clin Oncol* 2007;25:4895-4901.
383. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. *J Clin Oncol* 2005;23:4330-4337.
384. Rohatgi R, Swisher SG, Correa AM, et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. *Cancer* 2005;106:552-558.
385. Swisher SG, Hofsetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). *Ann Surg* 2005;241:810-817.
386. Swisher SG, Winter KA, Komaki RU, et al. A phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. *Int J Radiat Oncol Biol Phys* 2012;82:1967-1972.
387. Gaca JG, Petersen RP, Peterson BL, et al. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. *Ann Surg Oncol* 2006;13:340-346.
388. Morita M, Kuwano H, Araki K, et al. Prognostic significance of lymphocytic infiltration following preoperative chemoradiotherapy and hyperthermia for esophageal cancer. *Int J Radiat Oncol Biol Phys* 2001;49:1259-1266.
389. Alexander BM, Wang XZ, Niemierko A, et al. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer. *Int J Radiat Oncol Biol Phys* 2012;83:164-171.
390. Kuwahara A, Yamamori M, Fujita M, et al. TNFRSF1B A 1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. *J Exp Clin Cancer Res* 2010;29:100(abstr).
391. Yi Y, Li B, Sun H, et al. Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. *Tumour Biol* 2010;31:333-340.
392. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappa B with chemoradiation resistance and poor outcome in esophageal carcinoma. *J Clin Oncol* 2006;24:748-754.
393. Izzo JG, Wu TT, Wu X, et al. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. *J Clin Oncol* 2007;25:698-707.
394. Hildebrandt M, Yang H, Hung M, et al. Genetic variations in the PI3K/PTEN/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. *J Clin Oncol* 2009;27:857-871.
395. Skinner HD, Xu E, Lee JH, et al. A validated miRNA expression profile for response to neoadjuvant therapy in esophageal cancer. *Proc ASCO* 2013;31:4078(abstr).

396. Kalha I, Kaw M, Fukami N, et al. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. *Cancer* 2004;101:940-947.
397. Blackstock AW, Farmer MR, Lovato J, et al. A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 2006;64:455-460.
398. Brucher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. *Cancer* 2006;106:2119-2127.
399. McLoughlin J, Melis M, Siegel E, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer. *J Am Coll Surg* 2008;206:879-886.
400. Sarbia M, Stahl M, Fink U, et al. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. *Clin Cancer Res* 1998;4:2991-2997.
401. Pomp J, Davelaar J, Blom J, et al. Radiotherapy for oesophagus carcinoma: the impact of p53 on treatment outcome. *Radiother Oncol* 1998;46:179-184.
402. Merchant TE, Minsky BD, Lauwers CY, et al. Esophageal cancer phospholipids correlated with histopathologic findings: a 31P NMR study. *NMR Biomed* 1999;12:184-188.
403. Hayashida Y, Honda K, Osaka Y, et al. Possible prediction of chemoradio-sensitivity of esophageal cancer by serum protein profiling. *Clin Cancer Res* 2005;11:8042-8047.
404. Chang JY, Zhang X, Komaki R, et al. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2006;64:1482-1494.
405. Nomiya T, Nemoto K, Miyachi H, et al. Relationships between radiosensitivity and microvascular density in esophageal carcinoma: significance of hypoxic fraction. *Int J Radiat Oncol Biol Phys* 2004;58:589-596.
406. Izquierdo MA, Marcuello E, Gomez de Segura G, et al. Unresectable non-metastatic squamous cell carcinoma of the esophagus managed by sequential chemotherapy (cisplatin and bleomycin) and radiation therapy. *Cancer* 1993;71:287-292.
407. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. *J Clin Oncol* 2003;21:2697-2702.
408. Wiedler HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. *J Clin Oncol* 2004;22:900-908.
409. Amini A, Ajani J, Komaki R, et al. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. *Ann Surg Oncol* 2014;21:306-314.
410. Armstrong JG. High dose rate remote afterloading brachytherapy for lung and esophageal cancer. *Sem Radiat Oncol* 1993;4:270-277.
411. Maingon P, d'Hombres A, Truc G, et al. High dose rate brachytherapy for superficial cancer of the esophagus. *Int J Radiat Oncol Biol Phys* 2000;46:71-76.
412. Homs MY, Essink-Bot ML, Borsboom GJ, et al. Quality of life after palliative treatment for oesophageal carcinoma—a prospective comparison between stent placement and single dose chemotherapy. *Eur J Cancer* 2004;40:1862-1871.
413. Okawa T, Dokiya T, Nishio M, et al. Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. *Int J Radiat Oncol Biol Phys* 1999;45:623-628.
414. Pasquier D, Mirabel X, Adenis A, et al. External beam radiation therapy followed by high-dose-rate brachytherapy for inoperable superficial esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2006;65:1456-1461.
415. Yorozu A, Toya K, Dokiya T. Long-term results of concurrent chemoradiotherapy followed by high dose rate brachytherapy for T2-3N0-1M0 esophageal cancer. *Esophagus* 2006;3:1.
416. Caspers RJ, Zwinideman AH, Griffioen G, et al. Combined external beam and low dose rate intraluminal radiotherapy in oesophageal cancer. *Radiother Oncol* 1993;27:7-12.
417. Yorozu A, Dokiya T, Oki Y, et al. Curative radiotherapy with high-dose-rate brachytherapy boost for localized esophageal carcinoma: dose-effect relationship of brachytherapy with the balloon type applicator system. *Radiother Oncol* 1999;51:133-139.
418. Ishikawa H, Nonaka T, Sakurai H, et al. Usefulness of intraluminal brachytherapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results. *Int J Rad Oncol Biol Phys* 2010;76:452-459.
419. Gaspar LE, Qian C, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report. *Int J Radiat Oncol Biol Phys* 1997;37:593-599.
420. Thomas CR, Berkey BA, Minsky BD, et al. Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. *Int J Radiat Oncol Biol Phys* 2004;58:1405-1410.
421. Gaspar LE, Nag S, Herskovic A, et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. *Int J Radiat Oncol Biol Phys* 1997;38:127-132.
422. Zhang Z, Liao Z, Jin J, et al. Dose response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. *Int J Radiat Oncol Biol Phys* 2005;61:656-664.
423. Wang Y, Shi XH, He SQ, et al. Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2002;54:131-136.
424. Zaho KL, Shi XH, Jiang GL, et al. Late course accelerated hyperfractionated radiotherapy for localized esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2004;60:123-129.
425. Choi N, Park SD, Lynch T, et al. Twice-daily radiotherapy as concurrent boost technique during chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of a phase II study. *Int J Radiat Oncol Biol Phys* 2004;50:111-122.
426. Chandra A, Guerrero TM, Liu HH, et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. *Radiother Oncol* 2005;77:247-253.
427. Fenkel L, Kaminsky I, Breen S, et al. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. *Radiother Oncol* 2008;89:287-291.
428. Kole TP, Aghayere O, Kwah J, et al. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. *Int J Radiat Oncol Biol Phys* 2012;83:1580-1586.
429. Yin L, Wu H, Gong J, et al. Volumetric-modulated arc therapy vs. c-IMRT in esophageal cancer: a treatment planning comparison. *World J Gastroenterol* 2012;18:5266-5275.
430. Nicolini G, Ghosh-Laskar S, Shrivastava SK, et al. Volumetric modulation arc radiotherapy with flattening filter-free beams compared with a static gantry IMRT and 3D conformal radiotherapy for advanced esophageal carcinoma: a feasibility study. *Int J Radiat Oncol Biol Phys* 2012;84:553-560.
431. Martin S, Chen JZ, Rashid Dar A, et al. Dosimetric comparison of helical tomotherapy, rapid arc, and a novel IMRT & arc technique for esophageal carcinoma. *Radiother Oncol* 2011;101:431-437.
432. Vivekanandan N, Sriram P, Kumar SA, et al. Volumetric modulated arc therapy for esophageal cancer. *Med Dosim* 2011;37:108-113.
433. Yin Y, Chen J, Xing L, et al. Applications of IMAT in cervical esophageal cancer radiotherapy: a comparison with fixed-field IMRT in dosimetry and implementation. *J Appl Clin Med Phys* 2011;12:3343.
434. Van Benthuysen L, Hales L, Podgorsak MB. Volumetric modulated arc therapy vs. IMRT for the treatment of distal esophageal cancer. *Med Dosim* 2011;36:404-409.
435. Gong Y, Wang S, Zhou L, et al. Dosimetric comparison using different multileaf collimators in intensity-modulated radiotherapy for upper thoracic esophageal cancer. *Radiother Oncol* 2010;5:65.
436. Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys* 2012;84:1078-1085.
437. Wang SL, Liao Z, Liu H, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. *World J Gastroenterol* 2006;14:5501-5508.
438. La TH, Minn AY, Su Z, et al. Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. *Dis Esoph* 2010;23:300-308.
439. Li XA, Chibani O, Greenwald B, et al. Radiotherapy dose perturbation of metallic esophageal stents. *Int J Radiat Oncol Biol Phys* 2002;54:1276-1285.
440. Nishimura Y, Nagata K, Katano S, et al. Severe complications in advanced esophageal cancer treated with radiotherapy after intubation of esophageal stents: a questionnaire survey of the Japanese Society for Esophageal Diseases. *Int J Radiat Oncol Biol Phys* 2003;56:1327.
441. Wara WM, Mauch PM, Thomas AN, et al. Palliation for carcinoma of the esophagus. *Radiology* 1976;121:717-720.
442. Petrovich Z, Langholz B, Formenti S, et al. Management of carcinoma of the esophagus: the role of radiotherapy. *Am J Clin Oncol* 1991;14:80-86.
443. Whittington R, Coia LR, Haller DG, et al. Adenocarcinoma of the esophagus and esophagogastric junction: the effects of single and combined modalities on the survival and patterns of failure following treatment. *Int J Radiat Oncol Biol Phys* 1990;19:593-603.
444. Caspers RJ, Welvaart K, Verkes RJ, et al. The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer. *Radiother Oncol* 1988;12:15-23.
445. Seitz JF, Giovannini M, Padata-Cesana J, et al. Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. *Cancer* 1990;66:214-219.
446. Harvey JA, Bessell JR, Beller E, et al. Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. *Dis Esophagus* 2004;17:260-265.
447. Algan O, Coia LR, Keller SM, et al. Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies. *Int J Radiat Oncol Biol Phys* 1995;32:753-761.
448. Gill PG, Denham JW, Jamieson GG, et al. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. *J Clin Oncol* 1992;10:1037-1043.



449. Urba S, Orringer M, Turrisi A, et al. A randomized trial comparing transhiatal esophagectomy (THE) to preoperative concurrent chemoradiation (CT/XRT) followed by esophagectomy in local regional esophageal carcinoma. *Proc Am Soc Clin Oncol* 1995;14:199.
450. Coia LR, Soffen EM, Schultheis TE, et al. Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. *Cancer* 1993;71:281–286.
451. O'Rourke IC, Tiver K, Bull C, et al. Swallowing performance after radiation therapy for carcinoma of the esophagus. *Cancer* 1988;61:2022–2026.
452. Sur M, Sur R, Cooper K, et al. Morphologic alterations in esophageal squamous cell carcinoma after preoperative high dose rate intraluminal brachytherapy. *Cancer* 1996;77:2200–2205.
453. Gschossman JM, Bonner JA, Foote RL, et al. Malignant tracheoesophageal fistula in patients with esophageal cancer. *Cancer* 1993;72:1513–1521.
454. Muto M, Ohtsu A, Miyamoto S, et al. Concurrent chemoradiotherapy for esophageal carcinoma with malignant fistulae. *Cancer* 1999;86:1406–1413.
455. Minsky BD. The adjuvant treatment of esophageal cancer. *Semin Radiat Oncol* 1994;4:165–169.
456. Werner-Wasik M, Yorke E, Deasy J, et al. Radiation dose-volume effects in the esophagus. *Int J Radiat Oncol Biol Phys* 2010;76:S86–S93.
457. Gergel TJ, Leichmann LL, Nava HR, et al. Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer: dose-volume histogram analysis. *Cancer J* 2002;8:451–460.
458. Lorche F, Dumas JL, Noel A, et al. Esophageal cancer: determination of internal target volume for conformal radiotherapy. *Radiother Oncol* 2006;80:327–332.
459. Yaremko B, Guerrero T, McAleer M, et al. Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography. *Int J Rad Oncol Biol Phys* 2008;70:145–153.
460. Sugahara S, Tokuyue K, Okumura T, et al. Clinical results of proton beam therapy for cancer of the esophagus. *Int J Radiat Oncol Biol Phys* 2005;61:76–84.
461. Koyama S, Hirohiko T. Proton beam therapy with high dose irradiation for superficial and advanced esophageal carcinomas. *Clin Cancer Res* 2003;9:3571–3577.
462. Lin SH, Komaki R, Liao Z, et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys* 2012;83:e345–e351.
463. Leong T, Everitt C, Yuen K, et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. *Radiother Oncol* 2006;78:254–261.
464. Sakurada A, Takahara T, Kwee TC, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal carcinoma. *Eur Radiol* 2009;19:1461–1469.
465. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. *Int J Radiat Oncol Biol Phys* 2003;55:724–735.
466. Willner J, Jost A, Baier K, et al. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. *Strahlenther Onkol* 2003;179:548–556.
467. Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. *Int J Radiat Oncol Biol Phys* 2002;54:329–339.
468. Schallenkamp J, Miller R, Brinkmann D, et al. Incidence of radiation pneumonitis after thoracic irradiation; Dose-Volume correlates. *Int J Radiat Oncol Biol Phys* 2007;67:410–416.
469. Wang S, Liao Z, Wej X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). *Int J Radiat Oncol Biol Phys* 2006;66:1399–1407.
470. Konski A, Li T, Christensen M, et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. *Radiother Oncol* 2012;104:72–77.
471. Rueth NM, Shaw D, D'Cunha J, et al. Esophageal stenting and radiotherapy: a multimodal approach for the palliation of symptomatic malignant dysphagia. *Ann Surg Oncol* 2012;19:4223–4228.
472. Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. *Ann Intern Med* 1972;77:861–870.
473. Stephens FO. Bleomycin—a new approach in cancer chemotherapy. *Med J Aust* 1973;1:1277–1283.
474. Ravry M, Moertel CG, Schutt AJ, et al. Treatment of advanced squamous cell carcinoma of the gastrointestinal tract with bleomycin (NSC-125066). *Cancer Chemother Rep* 1973;57:493–495.
475. Tancini G, Bajetta E, Bonadonna G. [Bleomycin alone and in combination with methotrexate in the treatment of carcinoma of the esophagus]. *Tumori* 1974;60:65–71.
476. Kolaric K, Maricic Z, Dujmovic I, et al. Therapy of advanced esophageal cancer with bleomycin, irradiation and combination of bleomycin with irradiation. *Tumori* 1976;62:255–262.
477. Lokich JJ, Shea M, Chaffey J. Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. *Cancer* 1987;60:275–279.
478. Ezdinli EZ, Gelber R, Desai DV, et al. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. *Cancer* 1980;46:2149–2153.
479. Engstrom PF, Lavin PT, Klaassen DJ. Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. *Cancer Treat Rep* 1983;67:713–715.
480. Whittington RM, Close HP. Clinical experience with mitomycin C (NSC-26980). *Cancer Chemother Rep* 1970;54:195–198.
481. Kolaric K, Maricic Z, Roth A, et al. Combination of bleomycin and adriamycin with and without radiation on the treatment of inoperable esophageal cancer. A randomized study. *Cancer* 1980;45:2265–2273.
482. Advani SH, Saikia TK, Swaroop S, et al. Anterior chemotherapy in esophageal cancer. *Cancer* 1985;56:1502–1506.
483. Bleiberg H, Conroy T, Paillet B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. *Eur J Cancer* 1997;33:1216–1220.
484. Davis S, Shammugathasa M, Kessler W. cis-Dichlorodiammineplatinum(II) in the treatment of esophageal carcinoma. *Cancer Treat Rep* 1980;64:709–711.
485. Miller JI, McIntyre B, Hatcher CR Jr. Combined treatment approach in surgical management of carcinoma of the esophagus: a preliminary report. *Ann Thorac Surg* 1985;40:289–293.
486. Panettiére FJ, Leichman LP, Tilchen EJ, et al. Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study. *Cancer Treat Rep* 1984;68:1023–1024.
487. Ravry M, Moore M. Phase II pilot study of cisplatin (II) in advanced squamous cell esophageal cancer. *Proc Am Soc Clin Oncol* 1980;21:353.
488. Conroy T, Etienne PL, Adenis A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer. Gastrointestinal Treat Cancer Cooperative Group. *J Clin Oncol* 1996;14:164–170.
489. Bidoli P, Stani SC, DeCandis D, et al. Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus. *Tumori* 2001;87:299–302.
490. Conroy T, Etienne PL, Adenis A, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. *Ann Oncol* 2002;13:721–729.
491. Kulke MH, Muzikansky A, Clark J, et al. A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. *Cancer Invest* 2006;24:346–350.
492. Milas L, Hunter NR, Mason KA, et al. Enhancement of tumor radio response of a murine mammary carcinoma by paclitaxel. *Cancer Res* 1994;54:3506–3510.
493. Ajani JA, Ison DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086–1091.
494. Anderson SE, O'Reilly EM, Kelsen DP, et al. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. *Cancer Invest* 2003;21:512–516.
495. Ison DH, Wadleigh S, Leichman L, et al. Paclitaxel by weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 2007;18:898–902.
496. Heath EI, Urba S, Marshall J, et al. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. *Invest New Drugs* 2002;20:95–99.
497. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. *Ann Oncol* 2004;15:955–959.
498. Bajorin D, Kelsen D, Heelan R. Phase II trial of dichloromethotrexate in epidermoid carcinoma of the esophagus. *Cancer Treat Rep* 1986;70:1245–1246.
499. Alberts AS, Falkson G, Badata M, et al. Trimetrexate in advanced carcinoma of the esophagus. *Invest New Drugs* 1988;6:319–321.
500. Brown T, Fleming T, Tangen C, et al. A phase II trial of trimetrexate in the treatment of esophageal cancer. A Southwest Oncology Group Trial. *Proc Am Soc Clin Oncol* 1992;11:(abst A479).
501. Coonley C, Bains M, Kelsen DP. VP-16-213 in the treatment of esophageal cancer: a phase II trial. *Cancer Treat Rep* 1983;67:397–398.
502. Radice PA, Bunn PA Jr, Ihde DC. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. *Cancer Treat Rep* 1979;63:1231–1239.
503. Kok TC, Van Der Gaast A, Splinter TA, et al. Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group. *Eur J Cancer* 1991;27:1112–1114.
504. Nanus DM, Kelsen DP, Lipperman R, et al. Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpected severe toxicity. *Invest New Drugs* 1988;6:239–241.
505. Mannell A, Winters Z. Carboplatin in the treatment of oesophageal cancer. *S Afr Med J* 1989;76:213–214.
506. Queisser W, Preusser P, Mross KB, et al. Phase II evaluation of carboplatin in advanced esophageal carcinoma. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. *Onkologie* 1990;13:190–193.
507. Harstrick A, Bokemeyer C, Preusser P, et al. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. *Cancer Chemother Pharmacol* 1992;29:321–322.

508. Sandler AB, Kindler HL, Einhorn LH, et al. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. *Ann Oncol* 2000;11:1161–1164.
509. MacDonald JS, Jacobson JL, Ketchel SJ, et al. A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339). *Invest New Drugs* 2000;18:199–202.
510. Asbury RF, Lipsitz S, Graham D, et al. Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group Study (E2293). *Am J Clin Oncol* 2000;23:45–46.
511. Enzinger C, Kulke MH, Clark WH, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. *Dig Dis Sci* 2005;20:2218–2223.
512. Lin L, Hecht JR. A Phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal junction. *Proc Am Soc Clin Oncol* 2000;19:1130.
513. Dinwoodie WR, Bartolucci AA, Lyman GH, et al. Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group Trial. *Cancer Treat Rep* 1986;70:267–270.
514. Kelsen DP, Fein R, Coonley C, et al. Cisplatin, vindesine, and mitoguazone in the treatment of esophageal cancer. *Cancer Treat Rep* 1986;70:255–259.
515. Chapman R, Fleming TR, Van Damme J, et al. Cisplatin, vinblastine, and mitoguazone in squamous cell carcinoma of the esophagus: a Southwest Oncology Group Study. *Cancer Treat Rep* 1987;71:1185–1187.
516. Ogura T, Hiramatsu Y, Araki H, et al. Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy. *Gan To Kagaku Ryoho* 1995;22:433–438.
517. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. *J Clin Oncol* 1997;15:261–267.
518. Ross P, Nicholson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol* 2002;20:1996.
519. Mauer AM, Kraut EH, Krauss SA, et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. *Ann Oncol* 2005;16:1320–1325.
520. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008;358:36–46.
521. Al-Batran S, Hartmann J, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435–1442.
522. Kang YK, Kang KW, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. *Ann Oncol* 2009;20:666–673.
523. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS Trial): a phase III trial. *Lancet Oncol* 2008;9:215–221.
524. Ajani JR, Correa A, Walsh G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS Trial. *J Clin Oncol* 2010;28:1547–1553.
525. Van Cutsem E, Moiseyenko VM, Tjulandini S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. *J Clin Oncol* 2006;24:4991–4997.
526. Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with esophagogastric cancer: a randomized trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). *Eur J Cancer* 2013;49:835–842.
527. Wadler S, Fell S, Haynes H, et al. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. *Cancer* 1993;71:1726–1730.
528. Ison DH, Sirott M, Saltz L, et al. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. *Cancer* 1995;75:2197–2202.
529. Wadler S, Haynes H, Beitler J, et al. Phase II clinical trial with 5-FU, interferon-alpha-2b and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. *Cancer* 1996;78:30–34.
530. Kelsen D, Lovett D, Wong J, et al. Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. *J Clin Oncol* 1992;10:269–274.
531. Bazarbashi S, Rahal M, Raja MA, et al. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. *Chemotherapy* 2002;48:211–216.
532. Kok TC, Van Der Gaast A, Dees J, et al. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. *Br J Cancer* 1996;74:980–984.
533. Polec MB, Kok TC, Siersema PD, et al. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folic acid in patients with advanced squamous cell carcinoma of the esophagus. *Anticancer Drugs* 2001;12:513–517.
534. Spiridonidis CH, Laufman LR, Jones JJ, et al. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. *Cancer* 1996;77:2070–2077.
535. Polec MB, Eskens FA, Van Der Burg ME, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. *Br J Cancer* 2002;86:669–673.
536. Polec MB, Verweij J, Siersema PD, et al. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. *Eur J Cancer* 2002;38:1495–1500.
537. Ison DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316–323.
538. Polec MB, Sparreboom A, Eskens FA, et al. A Phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. *Clin Cancer Res* 2004;10:1928–1934.
539. Ison DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. *J Clin Oncol* 1998;16:1826–1834.
540. Ison DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. *J Clin Oncol* 1999;17:3270–3275.
541. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. *Cancer* 2002;94:641–646.
542. Enzinger PC, Ryan D, Clark J, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. *Ann Oncol* 2009;20:475–480.
543. Enzinger PC, Burtess BA, Hollis DR, et al. CALGB 80403 / ECOG 1206: Randomized phase II study of standard chemotherapy plus cetuximab for metastatic esophageal cancer. *J Clin Oncol* 2010;28:155.
544. Hecht JR, Blanke CD, Benson AB, et al. Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. *Oncology* 2003;17:13–15.
545. Jatoi A, Tirona MT, Cha SS, et al. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. *Int J Gastrointest Cancer* 2002;32:115–123.
546. Govindan R, Read W, Faust J, et al. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. *Oncology (Williston Park)* 2003;17:27–31.
547. Burtess B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. *Ann Oncol* 2009;20:1242–1248.
548. Lordick F, von Schilling C, Bernhard H, et al. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. *Br J Cancer* 2003;89:630–633.
549. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol* 2008;19:1450–1457.
550. Airolidi M, Cortesina G, Giordano C, et al. Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. *Med Oncol* 2003;20:19–24.
551. Lorenzen S, Duyster RJ, Lersch C, et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. *Br J Cancer* 2005;92:2129–2133.
552. Bang YJ, Van Cutsem E, Feverislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. *Lancet* 2010;376:687–697.
553. Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/Erbb2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. *Clin Cancer Res* 2012;18:546–554.
554. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second line treatment of advanced esophageal cancer patients. *J Clin Oncol* 2006;24:1612–1619.
555. Ferry D, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. *Clin Cancer Res* 2007;13:5869–5875.
556. Dragovich T, McCoy S, LaFleur B, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinoma. *J Clin Oncol* 2006;24:4922–4927.
557. Dutton SJ, Blazeby JM, Petty RD, et al. Patient-reported outcomes from a phase III multicenter, randomized double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG). *J Clin Oncol* 2012;30:S34.
558. Pinto C, DiFabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. *Ann Oncol* 2006;18:510–517.
559. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin 5-fluorouracil versus cisplatin 5-fluorouracil alone in first line metastatic squamous cell carcinoma of the esophagus: a randomized phase II trial. *Ann Oncol* 2009;20:1667–1673.
560. Lordick F, Lubber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first line metastatic gastric cancer: a phase II study. *Br J Cancer* 2010;102:500–505.

561. Enzinger PC, Burtress BA, Hollis DR, et al. CALGB 80403/ECOG 1206: Randomized phase II study of standard chemotherapy plus cetuximab for metastatic esophageal cancer. *J Clin Oncol* 2010;28:15S.
562. Waddell T, Cunningham D, Gonzalez D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated esophagogastric cancer (REAL-3): a randomized, open-label phase 3 trial. *Lancet Oncol* 2013;14:481.
563. Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated gastric cancer (EXPAND): a randomized, open-label phase 3 trial. *Lancet Oncol* 2013;14:490-499.
564. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009;20:1667-1673.
565. Shah MA, Ramanathan RA, Ilson DH, et al. Multicenter phase II trial of irinotecan, cisplatin, and Bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. *J Clin Oncol* 2006;24:5201-5206.
566. Ohtsu A, Shah MA, van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol* 2011;29:3968-3976.
567. Fuchs CS, Tomasek J, Yang CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomized, multicenter, placebo-controlled, phase 3 trial. *Lancet* 2014;383:31-39.
568. Ohtsu A, Ajani JA, Bai YX, et al. Everolimus in previously treated, advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 Study. *J Clin Oncol* 2013;31:3935-3943.